الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

mylan ireland limited - fingolimod vesinikkloriid - sclerosis multiplex, relapsing-remitting - immunosupressandid - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1)orpatients kiiresti arenev raske relapsing remitting sclerosis multiplex määratud 2 või enam puuet ägenemiste ühe aasta, ja on 1 või enam gadoliinium suurendada kahjustused aju mri või olulist kasvu, t2 kahjustus koormus võrreldes varasema hiljutise mrt.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

mylan ireland limited - fingolimod vesinikkloriid - sclerosis multiplex, relapsing-remitting - immunosupressandid - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

mylan pharmaceuticals limited - darunaviiri - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):ravi hiv-1 nakkuse retroviirusevastast ravi (art)-kogenud täiskasvanud patsientidele, sealhulgas neid, mis on väga eeltöödeldud. ravi hiv-1 nakkuse pediaatrilised patsiendid alates vanusest 3 aastat ja vähemalt 15 kg kehakaalu kohta. otsustades ravi alustada darunavir co-manustatakse koos väikeses annuses ritonaviiri, tuleks hoolikalt kaaluda ravi ajalugu konkreetse patsiendi ja mustreid mutatsioonid on seotud erinevate mõjurite. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 ja 5. darunavir co-manustatakse koos väikeses annuses ritonaviir on näidustatud kombinatsioonis teiste viirusevastase ravimitega ravi patsientidel, kellel on inimese immuunpuudulikkuse viiruse (hiv-1) nakkus.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. otsustades ravi alustada darunavir sellisel kunsti-kogenud patsientidel, genotypic katsetamine peaks juhendi kasutamine darunavir (vt lõigud 4. 2, 4. 3, 4. 4 ja 5.

أستونيا - الإستونية - Ravimiamet

mylan pharmaceuticals limited - alendroonhape+kolekaltsiferool - tablett - 70mg+2800rÜ 12tk; 70mg+2800rÜ 4tk

أستونيا - الإستونية - Ravimiamet

mylan pharmaceuticals limited - alendroonhape+kolekaltsiferool - tablett - 70mg+5600rÜ 12tk

أستونيا - الإستونية - Ravimiamet

mylan pharmaceuticals limited - lamivudiin+abakaviir - õhukese polümeerikattega tablett - 300mg+600mg 60tk; 300mg+600mg 90tk; 300mg+600mg 30tk

أستونيا - الإستونية - Ravimiamet

mylan ireland limited - posakonasool - suukaudne suspensioon - 40mg 1ml 105ml 1tk

أستونيا - الإستونية - Ravimiamet

mylan pharmaceuticals limited - agomelatiin - õhukese polümeerikattega tablett - 25mg 98tk; 25mg 28tk; 25mg 56tk; 25mg 42tk; 25mg 100tk

أستونيا - الإستونية - Ravimiamet

mylan s.a.s. - doksorubitsiin - infusioonilahuse kontsentraat - 2mg 1ml 5ml 1viaal; 2mg 1ml 100ml 1viaal; 2mg 1ml 10ml 1viaal; 2mg 1ml 25ml 1viaal

أستونيا - الإستونية - Ravimiamet

mylan s.a.s. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 1000mg 1tk